HOME >> MEDICINE >> NEWS
Early HIV screening prolongs life and is affordable, Stanford study shows
Post Your Comments:
(Date:11/26/2014)... The report “Laboratory Information System/LIS Market by ... End User Labs (Clinical, Molecular Diagnostic, Blood Bank, ... Global Forecast to 2019” provides a detailed overview ... market trends, and strategies impacting the LIS market ... revenue and market growth. , Browse 85 market ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... Cardiology have launched a partnership designed to improve ... for congestive heart failure (CHF) patients in the ... staff and Lourdes Cardiology team will help CHF ... supervised protocols. This partnership pairs the Cardiac Recovery ...
(Date:11/26/2014)... November 26, 2014 The American ... the Association’s new director of meetings and conferences. ... annual meeting, special events and conferences. , ... this post,” said AAA Executive Director Ed Liebow. ... enthusiasm and energy. She was recognized in January ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 The city ... water shortages, is moving forward with a plan to ... water.* Radio host Sharon Kleyne supports the San Diego ... Water Management” (TWM). According to Kleyne, by recycling water ... import new water could be greatly reduced. (Spagat, E, ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 With a ... surgeon Dr. Steven Meier has enhanced the user ... current and prospective patients an online destination for orthopedic ... excited to present the new and improved version of ... make it easier than ever for current and prospective ...
Breaking Medicine News(10 mins):Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen (NASDAQ: ... ) today announced that AMAGINE-2 TM , a pivotal, multi-arm ... than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary ... placebo at week 12. Brodalumab 210 mg given every two ... to be superior to Stelara on the primary endpoint of ...
(Date:11/26/2014)... DIEGO , Nov. 25, 2014 Halozyme Therapeutics, ... the Piper Jaffray Healthcare Conference in New York ... EDT/10:00 a.m. PDT . Dr. Helen Torley , ... The presentation will be webcast through the "Investors" ... a recording will be made available for 90 days following ...
(Date:11/24/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading medical ... surgery, announced today that it will participate in the upcoming ... December 3, 2014 at The New York Palace Hotel in ... live webcast of the Company,s presentation is scheduled to begin ... the company by Pat Mackin , President and Chief ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3
Cached News: